HomeCompareRVVTF vs CL

RVVTF vs CL: Dividend Comparison 2026

RVVTF yields 7692.31% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVVTF wins by $4177739098279589.00M in total portfolio value
10 years
RVVTF
RVVTF
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full RVVTF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — RVVTF vs CL

📍 RVVTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVVTFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVVTF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVVTF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVVTF
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, RVVTF beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVVTF + CL for your $10,000?

RVVTF: 50%CL: 50%
100% CL50/50100% RVVTF
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

RVVTF
No analyst data
Altman Z
-566.5
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVVTF buys
0
CL buys
0
No recent congressional trades found for RVVTF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVVTFCL
Forward yield7692.31%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$4177739098279589.00M$40.8K
Annual income after 10y$4,073,565,928,588,968,500,000.00$5,401.96
Total dividends collected$4170772265337663.00M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RVVTF vs CL ($10,000, DRIP)

YearRVVTF PortfolioRVVTF Income/yrCL PortfolioCL Income/yrGap
1← crossover$779,931$769,230.77$11,012$312.01+$768.9KRVVTF
2$56,904,315$56,069,789.30$12,196$412.95+$56.89MRVVTF
3$3,884,151,673$3,823,264,055.84$13,599$549.66+$3884.14MRVVTF
4$248,050,254,929$243,894,212,638.74$15,288$736.64+$248050.24MRVVTF
5$14,822,056,221,428$14,556,642,448,653.80$17,353$995.28+$14822056.20MRVVTF
6$828,776,618,419,079$812,917,018,262,150.50$19,926$1,357.80+$828776618.40MRVVTF
7$43,367,472,132,823,630$42,480,681,151,115,220.00$23,194$1,873.82+$43367472132.80MRVVTF
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$27,439$2,621.52+$2123871047251.56MRVVTF
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$33,088$3,727.38+$97358102514598.28MRVVTF
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$40,806$5,401.96+$4177739098279589.00MRVVTF

RVVTF vs CL: Complete Analysis 2026

RVVTFStock

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Full RVVTF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this RVVTF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVVTF vs SCHDRVVTF vs JEPIRVVTF vs ORVVTF vs KORVVTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.